Award follows Wall Street Journal recognition as a new technology worth watching. (Nov. 29, 2016) Click to view
Yearly Archive: 2016
Merck Tops as Lung Cancer Treatment Moves Past Chemotherapy
Bloomberg News reports that Merck is setting the pace in immunotherapy to fight lung tumors. (Oct. 9, 2016). Click to view.
New Lung Cancer Screening Data from Preora Diagnostics Published in Peer-Reviewed Biomedical Optics Express
Successful optimization study moves company forward toward commercialization of PWS Nanoctyology technology platform. (Sept. 22, 2016) Click to view.
PWS Nanocytology Platform Featured on National Podcast
In the first episode of its “Amazing Things” podcast series, the national United for Medical Research coalition featured Northwestern Professor and Preora Chairman Vadim Backman, who explains why PWS Nanocytology is a breakthrough method for detecting cancer earlier than ever. (Sept. 13, 2016) Click to view
Early prostate cancer diagnoses on the decline
The Chicago Tribune (Aug. 22, 2016) covered the ongoing debate regarding the pros and cons of the PSA screening test.
Click here to read the full story:
Chicago Tribune
Preora Diagnostics Presenting at AdvaMed 2016’s High-profile “Innovation Showcase”
Company also participating in RESI and Cavendish conferences in September 2016.
Click here to read the full story.
AdvaMed 2016 Innovation Showcase
Computers could be more accurate than pathologists in assessing lung cancer tissues
Stanford University researchers observed that computers had an edge over pathologists classifying tumors (August 2016)
Click here to read the full story.
Stanford University
PWS Nanocytology Platform Named one of “Six New Medical Technologies Worth Watching”
The Wall Street Journal (June 26, 2016) highlighted our screening tests as an emerging technology that “could have a big impact on medicine in the coming years.”
Click here to read the full story.
Wall Street Journal Article
Study Links Air Pollution to Lung Cancer Survival Time
According to USC research published in the medical journal Thorax, survival of patients in areas with high regional pollution was about three years shorter than for those in areas with lower levels of pollution. (Aug. 5, 2016) Click to view.
iBIO PROPEL Highlights Preora Diagnostics
In its semi-annual newsletter to investors, the Illinois Biotechnology Industry Organization profiled Preora as a company to watch (excerpt from Feb. 2016 issue)
Click here to read the full story.
iBIO Newsletter